texas oncology more breakthroughs. more victories
  • Request an Appointment
  • Find a cancer center
  • Find a provider
  • Clinical Trials

Share:

 
 

Fort Worth Clinical Trials

Texas Oncology cancer centers in Fort Worth participate in a wide range of clinical trials and groundbreaking cancer research paving the way for new breakthroughs in cancer care. If you are a Texas Oncology patient in the Fort Worth area, you may be able to take part in these innovative clinical trials. Learn more and see a full list of current trials.

Our cancer researchers in the Fort Worth area are involved in several types of clinical trials:

  • Prevention trials focused on preventing cancer or recurrence. Trials might focus on the use of vitamins, different medications or a change in diet or exercise to determine if the risk of developing cancer is lowered.
  • Screening trials focused on identifying and detecting cancer in people who do not exhibit symptoms of cancer.
  • Diagnostic trials determining how to identify cancers using new tests. These trials often involve participants who show signs or symptoms of a particular cancer.
  • Treatment trials designed to answer questions about new treatments, such as drugs, surgical procedures, vaccines, or therapies involving current cancer patients.

Benefits and Risks

Discuss the benefits and risks with your physician if you're interested in participating in a clinical trial or cancer research in the Fort Worth area. Benefits include being actively involved in your healthcare, getting access to new treatments and medical care, and helping to further medical research. Risks may include unpleasant or serious side effects, treatments that are ineffective, and trials which take more time than standard treatment.

Eligibility

Your eligibility for a clinical trial depends on several criteria, including your age and sex, your cancer type and stage of the the cancer, previous treatments, and your overall medical history. View the list below of open clinical trials and cancer research opportunities in the Fort Worth area and talk to you doctor to determine which clinical trial is right for you.

Biliary Cancer

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Biliary Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Biliary Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Biliary Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR INCB054828 in Cholangiocarcinoma View

Description: A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202)

Indication: Biliary Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR INCB054828 in Cholangiocarcinoma View

Description: A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202)

Indication: Biliary Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR INCB054828 in Cholangiocarcinoma View

Description: A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202)

Indication: Biliary Cancer

Location: Texas Oncology-Fort Worth 8th Ave.

Phase: II

Brain Cancer

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Brain Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Title: Ph1/2 Roval Tesirine Solid Tumor View

Description: SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Indication: Brain Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Breast Cancer

Title: Pragmatic Phase III Randomized Trial Of Proton Vs. Photon Therapy For Patients With Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (Radcomp) Consortium Trial View

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Title: Pragmatic Phase III Randomized Trial Of Proton Vs. Photon Therapy For Patients With Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (Radcomp) Consortium Trial View

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Title: Alisertib+Pac MBC/local recurBC 1&2 Ln View

Description: (USO 13033/ Millennium X14021) A Phase II, Multicenter, Randomized, Parallel Group Study to Compare Alisertib in Combination with Paclitaxel vs. Paclitaxel Alone in Patients with Metastatic or Locally Recurrent Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Alisertib+Pac MBC/local recurBC 1&2 Ln View

Description: (USO 13033/ Millennium X14021) A Phase II, Multicenter, Randomized, Parallel Group Study to Compare Alisertib in Combination with Paclitaxel vs. Paclitaxel Alone in Patients with Metastatic or Locally Recurrent Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Alisertib+Pac MBC/local recurBC 1&2 Ln View

Description: (USO 13033/ Millennium X14021) A Phase II, Multicenter, Randomized, Parallel Group Study to Compare Alisertib in Combination with Paclitaxel vs. Paclitaxel Alone in Patients with Metastatic or Locally Recurrent Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Post-Mastctmy/Lumpctmy XRT, Neoadj Chemo View

Description: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP B-51 / RTOG 1304)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Title: STAR Open Label VT-464 Adv Breast Cancer View

Description: A Phase 1/2 Open-Label Study to Evaluate the Safety,Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel plus Dexamethasone (SEVI-D) in Subjects with Advanced Breast Cancer (INO-VT-464-CL-006)

Indication: Breast Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Open Label VT-464 Adv Breast Cancer View

Description: A Phase 1/2 Open-Label Study to Evaluate the Safety,Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel plus Dexamethasone (SEVI-D) in Subjects with Advanced Breast Cancer (INO-VT-464-CL-006)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Open Label VT-464 Adv Breast Cancer View

Description: A Phase 1/2 Open-Label Study to Evaluate the Safety,Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel plus Dexamethasone (SEVI-D) in Subjects with Advanced Breast Cancer (INO-VT-464-CL-006)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Open Label VT-464 Adv Breast Cancer View

Description: A Phase 1/2 Open-Label Study to Evaluate the Safety,Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel plus Dexamethasone (SEVI-D) in Subjects with Advanced Breast Cancer (INO-VT-464-CL-006)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: STAR Open Label VT-464 Adv Breast Cancer View

Description: A Phase 1/2 Open-Label Study to Evaluate the Safety,Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel plus Dexamethasone (SEVI-D) in Subjects with Advanced Breast Cancer (INO-VT-464-CL-006)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: PHIII AuxLymphDisect VS AuxRad Node+Brst View

Description: A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (ct1-3 n1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy

Indication: Breast Cancer

Location: Texas Oncology-Arlington North

Phase: III

Title: PHIII AuxLymphDisect VS AuxRad Node+Brst View

Description: A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (ct1-3 n1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: PHIII AuxLymphDisect VS AuxRad Node+Brst View

Description: A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (ct1-3 n1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph II G1T28+Gem&Carb mTNBC View

Description: Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients with Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy (G1T28-04)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph II G1T28+Gem&Carb mTNBC View

Description: Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients with Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy (G1T28-04)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Cape/tras +/- ONT-380 HER2+ mBC View

Description: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinibvs. Placebo in Combination with Capecitabine and Trastuzumab inPatients with Pretreated Unresectable Locally Advanced or MetastaticHER2+ Breast Carcinoma(HER2CLIMB) (ONT-380-206)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Cape/tras +/- ONT-380 HER2+ mBC View

Description: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinibvs. Placebo in Combination with Capecitabine and Trastuzumab inPatients with Pretreated Unresectable Locally Advanced or MetastaticHER2+ Breast Carcinoma(HER2CLIMB) (ONT-380-206)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Cape/tras +/- ONT-380 HER2+ mBC View

Description: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinibvs. Placebo in Combination with Capecitabine and Trastuzumab inPatients with Pretreated Unresectable Locally Advanced or MetastaticHER2+ Breast Carcinoma(HER2CLIMB) (ONT-380-206)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: STAR Cape/tras +/- ONT-380 HER2+ mBC View

Description: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinibvs. Placebo in Combination with Capecitabine and Trastuzumab inPatients with Pretreated Unresectable Locally Advanced or MetastaticHER2+ Breast Carcinoma(HER2CLIMB) (ONT-380-206)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Klabzuba

Phase: II

Title: STAR Cape/tras +/- ONT-380 HER2+ mBC View

Description: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinibvs. Placebo in Combination with Capecitabine and Trastuzumab inPatients with Pretreated Unresectable Locally Advanced or MetastaticHER2+ Breast Carcinoma(HER2CLIMB) (ONT-380-206)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Cape/tras +/- ONT-380 HER2+ mBC View

Description: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinibvs. Placebo in Combination with Capecitabine and Trastuzumab inPatients with Pretreated Unresectable Locally Advanced or MetastaticHER2+ Breast Carcinoma(HER2CLIMB) (ONT-380-206)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth 8th Ave.

Phase: II

Title: Ph 3 Tesetaxel+Capecitabine mHER2- View

Description: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (ODO-TE-B301)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph 3 Tesetaxel+Capecitabine mHER2- View

Description: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (ODO-TE-B301)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph2 MLN0128 + Fulves ER+/HER2- mBC View

Description: An Open-Label Phase 2 Study of MLN0128 (A TORC1/2 Inhibitor) in Combination WithFulvestrant in Women With ER-Positive/HER2-Negative Advanced or Metastatic BreastCancer That Has Progressed During or After Aromatase Inhibitor Therapy. (C31006)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 MLN0128 + Fulves ER+/HER2- mBC View

Description: An Open-Label Phase 2 Study of MLN0128 (A TORC1/2 Inhibitor) in Combination WithFulvestrant in Women With ER-Positive/HER2-Negative Advanced or Metastatic BreastCancer That Has Progressed During or After Aromatase Inhibitor Therapy. (C31006)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of AbemaciclibCombined with Standard Adjuvant Endocrine Therapy versusStandard Adjuvant Endocrine Therapy Alone in Patients withHigh Risk, Node Positive, Early Stage, Hormone ReceptorPositive, Human Epidermal Receptor 2 Negative, BreastCancer

Indication: Breast Cancer

Location: Texas Oncology-Arlington North

Phase: III

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of AbemaciclibCombined with Standard Adjuvant Endocrine Therapy versusStandard Adjuvant Endocrine Therapy Alone in Patients withHigh Risk, Node Positive, Early Stage, Hormone ReceptorPositive, Human Epidermal Receptor 2 Negative, BreastCancer

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of AbemaciclibCombined with Standard Adjuvant Endocrine Therapy versusStandard Adjuvant Endocrine Therapy Alone in Patients withHigh Risk, Node Positive, Early Stage, Hormone ReceptorPositive, Human Epidermal Receptor 2 Negative, BreastCancer

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: III

Carcinoid

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Carcinoid

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Carcinoid

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Carcinoid

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Carcinoid

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Carcinoid

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Carcinoid

Location: Texas Oncology-Fort Worth 8th Ave.

Phase: II

Cervical Cancer

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Cervical Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Cervical Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Cervical Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Cervical Cancer

Location: Texas Oncology-Grapevine

Phase: II

Colon Cancer

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Title: Ph3 BBI-608/FOLFIRI +/- Bev, 2L mCRC View

Description: CanStem303C: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC)

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: III

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Endometrial Cancer

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Endometrial Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Endometrial Cancer

Location: Texas Oncology-Grapevine

Phase: II

Esophageal Cancer

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Esophageal Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Essential Thrombocythemia

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Essential Thrombocythemia

Location: Texas Oncology-Arlington North

Phase: IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Essential Thrombocythemia

Location: Texas Oncology-Arlington South

Phase: IV

Fallopian Tube Cancer

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, ANDBEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IVOVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, ANDBEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IVOVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: IMGN583, Folate Recept+ Ovrn [FORWARD 1] View

Description: FORWARD 1: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab soravtansine (IMGN853) Versus Investigator''s Choice of Chemotherapy in Women with Folate Receptor alpha-positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer (0403)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: III

Gastric Cancer

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Gastric Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Gastric Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Gastric Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Nivo+Ipi v Oxali+5FU, 1L Gastric/GEJ View

Description: CA209649: A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab plus Ipilimumab orNivolumab in Combination with Oxaliplatin plus Fluoropyrimidine versus Oxaliplatin plusFluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic Gastric orGastroesophageal Junction Cancer(CheckMate 649: CHECKpoint pathway and nivoluMab Clinical Trial Evaluation 649)

Indication: Gastric Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Nivo+Ipi v Oxali+5FU, 1L Gastric/GEJ View

Description: CA209649: A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab plus Ipilimumab orNivolumab in Combination with Oxaliplatin plus Fluoropyrimidine versus Oxaliplatin plusFluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic Gastric orGastroesophageal Junction Cancer(CheckMate 649: CHECKpoint pathway and nivoluMab Clinical Trial Evaluation 649)

Indication: Gastric Cancer

Location: Texas Oncology-Grapevine

Phase: III

Head and Neck Cancer

Title: IMRT+/-Cetuximab H&N View

Description: A phase III study of postoperative radiation therapy (IMRT) +/- cetuximab for locally-advanced resected head and neck cancer (RTOG 0920)

Indication: Head and Neck Cancer

Location: Texas Oncology-Fort Worth 8th Ave.

Phase: III

Title: IMRT+/-Cetuximab H&N View

Description: A phase III study of postoperative radiation therapy (IMRT) +/- cetuximab for locally-advanced resected head and neck cancer (RTOG 0920)

Indication: Head and Neck Cancer

Location: Texas Oncology-Fort Worth Klabzuba

Phase: III

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Head and Neck Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Head and Neck Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Head and Neck Cancer

Location: Texas Oncology-Grapevine

Phase: II

Hematologic

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Hematologic

Location: Texas Oncology-Arlington North

Phase: IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Hematologic

Location: Texas Oncology-Arlington South

Phase: IV

Leukemia

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Arlington North

Phase: IV

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Arlington South

Phase: IV

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Bedford

Phase: IV

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Grapevine

Phase: IV

Title: Ublituximab+TGR-1202 Cross-over View

Description: (UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304

Indication: Leukemia

Location: Texas Oncology-Bedford

Phase: II

Title: Ublituximab+TGR-1202 Cross-over View

Description: (UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304

Indication: Leukemia

Location: Texas Oncology-Grapevine

Phase: II

Liver Cancer

Title: PhIb/II BBI608/503+Sorafenib HCC View

Description: A Phase Ib/II Clinical Study of BBI608 in Combination with Sorafenib or BBI503 in Combination with Sorafenib in Adult Patients with Hepatocellular Carcinoma (BBI608-503-103HCC; formerly: BBIHCC-103)

Indication: Liver Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Liver Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Lung Cancer

Title: Phase III Randomized Study of Standard versus Accelerated Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients with Stage II-III Non-Small Cell Lung Cancer and Poor Performance Status View

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Title: Phase III Randomized Study of Standard versus Accelerated Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients with Stage II-III Non-Small Cell Lung Cancer and Poor Performance Status View

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: Ph2 Combo Therapies IO NSCLC-FRACTION View

Description: CA018-001/CA018-001A: Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Subjects with Advanced Non-small Cell Lung Cancer (FRACTION-Lung)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Ph 1a/1b Rovalpituzumab Extensive SCLC View

Description: SCRX001-004: A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients with Delta-Like Protein 3-Expressing Extensive Stage Small Cell Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Title: Ph1b/2 HBI8000+Nivo Advanced Solid Tumor View

Description: HBI-8000-302: A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Nivolumab in Patients with Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC) and Non-Small Cell Lung Cancer (NSCLC)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: Ph3b/4 Safety Nivo+Ipi 1L, 2L NSCLC View

Description: CA209-817: A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: III/IV

Title: Ph3 Nivo vs Plat-Doublet chemo NSCLC View

Description: Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC (CA209-816)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Nivo vs Plat-Doublet chemo NSCLC View

Description: Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC (CA209-816)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Lymphomas

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR CC-122+Rtx, FL R/R to Len View

Description: A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223, CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELLLYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001)

Indication: Lymphomas

Location: Texas Oncology-Arlington North

Phase: I

Title: STAR CC-122+Rtx, FL R/R to Len View

Description: A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223, CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELLLYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001)

Indication: Lymphomas

Location: Texas Oncology-Arlington South

Phase: I

Title: STAR CC-122+Rtx, FL R/R to Len View

Description: A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223, CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELLLYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001)

Indication: Lymphomas

Location: Texas Oncology-Bedford

Phase: I

Title: STAR CC-122+Rtx, FL R/R to Len View

Description: A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223, CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELLLYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Title: STAR CC-122+Rtx, FL R/R to Len View

Description: A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223, CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELLLYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Klabzuba

Phase: I

Title: STAR CC-122+Rtx, FL R/R to Len View

Description: A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223, CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELLLYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001)

Indication: Lymphomas

Location: Texas Oncology-Grapevine

Phase: I

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Arlington North

Phase: I/II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Fort Worth 8th Ave.

Phase: I/II

Melanoma

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Bedford

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Grapevine

Phase: I/II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Melanoma

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Title: Ph1b/2 HBI8000+Nivo Advanced Solid Tumor View

Description: HBI-8000-302: A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Nivolumab in Patients with Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC) and Non-Small Cell Lung Cancer (NSCLC)

Indication: Melanoma

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: Ph1/2 Roval Tesirine Solid Tumor View

Description: SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Indication: Melanoma

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: Ph3 Cobi + Atezo vs Pembro BRAF Melanoma View

Description: A PHASE III, OPEN-LABEL, MULTICENTER, TWO ARM, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF COBIMETINIB PLUS ATEZOLIZUMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED BRAFV600 WILD-TYPE MELANOMA (CO39722)

Indication: Melanoma

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: III

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Melanoma

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Mesothelioma

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Mesothelioma

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Mesothelioma

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Mesothelioma

Location: Texas Oncology-Grapevine

Phase: II

Miscellaneous

Title: A Retrospective Chart Review to Identify Common Factors Leading to Hospitalization of Patients with Gynecologic Cancers within 6 Months of Receiving Chemotherapy View

Indication: Miscellaneous

Location: Texas Oncology-Fort Worth 12th Ave.

Myelofibrosis

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Myelofibrosis

Location: Texas Oncology-Arlington North

Phase: IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Myelofibrosis

Location: Texas Oncology-Arlington South

Phase: IV

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Grapevine

Phase: II

Myelomas

Title: Multiple Myeloma Patient Registry View

Description: Multiple Myeloma Patient Registry

Indication: Myelomas

Location: Texas Oncology-Arlington North

Phase: IV

Title: Multiple Myeloma Patient Registry View

Description: Multiple Myeloma Patient Registry

Indication: Myelomas

Location: Texas Oncology-Arlington South

Phase: IV

Neuroendocrine Tumors

Title: STAR BSC +/- LAN in Lung NETs [SPINET] View

Description: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Arlington North

Phase: III

Title: STAR BSC +/- LAN in Lung NETs [SPINET] View

Description: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR BSC +/- LAN in Lung NETs [SPINET] View

Description: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Bedford

Phase: III

Title: STAR BSC +/- LAN in Lung NETs [SPINET] View

Description: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: III

Title: STAR BSC +/- LAN in Lung NETs [SPINET] View

Description: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Fort Worth 8th Ave.

Phase: III

Title: STAR BSC +/- LAN in Lung NETs [SPINET] View

Description: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Fort Worth Klabzuba

Phase: III

Title: STAR BSC +/- LAN in Lung NETs [SPINET] View

Description: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR BSC +/- LAN in Lung NETs [SPINET] View

Description: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Fort Worth 8th Ave.

Phase: III

Title: STAR BSC +/- LAN in Lung NETs [SPINET] View

Description: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Fort Worth 8th Ave.

Phase: III

Title: Ph1/2 Roval Tesirine Solid Tumor View

Description: SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Grapevine

Phase: II

Ovarian Cancer

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Title: Niraparib HRD+ Adv Ovrn post 1L [PRIMA] View

Description: PR-30-5017-C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response On Front-Line Platinum-Based Chemotherapy (PRIMA)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: III

Title: Ph2 NUC-1031 Pt-Resist Ovarian View

Description: A Phase II Open-Label Study of NUC-1031 in Patients with Platinum-Resistant Ovarian Cancer (PRO-105)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 NUC-1031 Pt-Resist Ovarian View

Description: A Phase II Open-Label Study of NUC-1031 in Patients with Platinum-Resistant Ovarian Cancer (PRO-105)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, ANDBEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IVOVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, ANDBEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IVOVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Ovarian Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: IMGN583, Folate Recept+ Ovrn [FORWARD 1] View

Description: FORWARD 1: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab soravtansine (IMGN853) Versus Investigator''s Choice of Chemotherapy in Women with Folate Receptor alpha-positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer (0403)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: III

Pancreatic Cancer

Title: Erlotinib + ChemoRad Pancreas Adeno View

Description: A Phase II-R and A Phase III Trial Evaluating Both *Erlotinib (Ph II-R) and Chemoradiation (PhIII) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma (RTOG 0848)

Indication: Pancreatic Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Pancreatic Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Title: Ph1/2 Roval Tesirine Solid Tumor View

Description: SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Indication: Pancreatic Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Penile Cancer

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Penile Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Penile Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Penile Cancer

Location: Texas Oncology-Grapevine

Phase: II

Peritoneal Cancer

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, ANDBEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IVOVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Peritoneal Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, ANDBEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IVOVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Peritoneal Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: IMGN583, Folate Recept+ Ovrn [FORWARD 1] View

Description: FORWARD 1: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab soravtansine (IMGN853) Versus Investigator''s Choice of Chemotherapy in Women with Folate Receptor alpha-positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer (0403)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: III

Prostate Cancer

Title: Ph3Andro+HighRad +/- PelvicRad Prostate View

Description: Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth 8th Ave.

Phase: III

Title: Ph3Andro+HighRad +/- PelvicRad Prostate View

Description: Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Klabzuba

Phase: III

Title: Enzal +/- PI3 Kinase/mTOR inhib mCRPC View

Description: A Double-Blinded, Placebo-Controlled, Randomized Phase II Study ofEnzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414in Men with Metastatic Castration Resistant Prostate Cancer (GU 115/I6A-MC-CBBD)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Ph1/2 Roval Tesirine Solid Tumor View

Description: SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: Ph3 aPDL1/Atezo+Enza mCRPC View

Description: A PHASE III, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH ENZALUTAMIDE VERSUS ENZALUTAMIDE ALONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF AN ANDROGEN SYNTHESISINHIBITOR AND FAILURE OF, INELIGIBILITY FOR, OR REFUSAL OF A TAXANE REGIMEN - Roche CO39385

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: III

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth 8th Ave.

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington North

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth 8th Ave.

Phase: III

Rectal Cancer

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Rectal Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Rectal Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Rectal Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Rectal Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph3 BBI-608/FOLFIRI +/- Bev, 2L mCRC View

Description: CanStem303C: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC)

Indication: Rectal Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: III

Renal Cancer

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: Ph1b/2 HBI8000+Nivo Advanced Solid Tumor View

Description: HBI-8000-302: A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Nivolumab in Patients with Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC) and Non-Small Cell Lung Cancer (NSCLC)

Indication: Renal Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: Ph2 Lenvatinib+evero RCC 2L View

Description: E7080-G000-218: A Randomized, Double-blind, Phase 2 Trial to Assess Safety and Efficacy of Lenvatinib at Two Different Starting Doses (18 mg vs. 14 mg QD) in Combination with Everolimus (5 mg QD) in Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment

Indication: Renal Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Lenvat+ever/pemb vs sunit 1L RCC [CLEAR] View

Description: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma(E7080-G000-307)(CLEAR)

Indication: Renal Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: III

Skin Cancer

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Fort Worth 8th Ave.

Phase: II

Solid Tumors

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Title: Ph1/2 Roval Tesirine Solid Tumor View

Description: SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: II

Title: PhIb/II BBI503+select therapy Adv Cancer View

Description: A Phase Ib/II Clinical Study of BBI503 in Combination with Selected Anti-Cancer Therapeutics in Adult Patients with Advanced Cancer - BBI503-201

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: Molec Markers - solid malignant tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: IV

Title: Molec Markers - solid malignant tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: IV

Title: Molec Markers - solid malignant tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: IV

Testicular Cancer

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Testicular Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Testicular Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Testicular Cancer

Location: Texas Oncology-Grapevine

Phase: II

Thymomas

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thymomas

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thymomas

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thymomas

Location: Texas Oncology-Grapevine

Phase: II

Thyroid Cancer

Title: Ph1/2 Roval Tesirine Solid Tumor View

Description: SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Indication: Thyroid Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thyroid Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thyroid Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thyroid Cancer

Location: Texas Oncology-Grapevine

Phase: II

Urothelial Cancer

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph3 Pembro+Epacadostat 2L UC View

Description: A Phase 3 Randomized, Double-Blind Clinical Study of Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo as a Treatment for Recurrent or Progressive Metastatic Urothelial Carcinoma in Patients who have Failed a First-Line Platinum-containing Chemotherapy Regimen for Advanced/Metastatic Disease (KEYNOTE-698/ECHO-303) (MK3475-KN698)

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington North

Phase: III

Title: STAR Ph3 Pembro+Epacadostat 2L UC View

Description: A Phase 3 Randomized, Double-Blind Clinical Study of Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo as a Treatment for Recurrent or Progressive Metastatic Urothelial Carcinoma in Patients who have Failed a First-Line Platinum-containing Chemotherapy Regimen for Advanced/Metastatic Disease (KEYNOTE-698/ECHO-303) (MK3475-KN698)

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph3 Pembro+Epacadostat 2L UC View

Description: A Phase 3 Randomized, Double-Blind Clinical Study of Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo as a Treatment for Recurrent or Progressive Metastatic Urothelial Carcinoma in Patients who have Failed a First-Line Platinum-containing Chemotherapy Regimen for Advanced/Metastatic Disease (KEYNOTE-698/ECHO-303) (MK3475-KN698)

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph3 Pembro+Epacadostat 2L UC View

Description: A Phase 3 Randomized, Double-Blind Clinical Study of Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo as a Treatment for Recurrent or Progressive Metastatic Urothelial Carcinoma in Patients who have Failed a First-Line Platinum-containing Chemotherapy Regimen for Advanced/Metastatic Disease (KEYNOTE-698/ECHO-303) (MK3475-KN698)

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: III

Title: STAR Ph3 Pembro+Epacadostat 2L UC View

Description: A Phase 3 Randomized, Double-Blind Clinical Study of Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo as a Treatment for Recurrent or Progressive Metastatic Urothelial Carcinoma in Patients who have Failed a First-Line Platinum-containing Chemotherapy Regimen for Advanced/Metastatic Disease (KEYNOTE-698/ECHO-303) (MK3475-KN698)

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: III

Uterine Cancer

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Uterine Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Uterine Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Uterine Cancer

Location: Texas Oncology-Grapevine

Phase: II

Vaginal Cancer

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Vaginal Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Vaginal Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Vaginal Cancer

Location: Texas Oncology-Grapevine

Phase: II

Texas Oncology-Arlington North

Title: STAR Open Label VT-464 Adv Breast Cancer View

Description: A Phase 1/2 Open-Label Study to Evaluate the Safety,Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel plus Dexamethasone (SEVI-D) in Subjects with Advanced Breast Cancer (INO-VT-464-CL-006)

Indication: Breast Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: PHIII AuxLymphDisect VS AuxRad Node+Brst View

Description: A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (ct1-3 n1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy

Indication: Breast Cancer

Location: Texas Oncology-Arlington North

Phase: III

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of AbemaciclibCombined with Standard Adjuvant Endocrine Therapy versusStandard Adjuvant Endocrine Therapy Alone in Patients withHigh Risk, Node Positive, Early Stage, Hormone ReceptorPositive, Human Epidermal Receptor 2 Negative, BreastCancer

Indication: Breast Cancer

Location: Texas Oncology-Arlington North

Phase: III

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Carcinoid

Location: Texas Oncology-Arlington North

Phase: II

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Essential Thrombocythemia

Location: Texas Oncology-Arlington North

Phase: IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Hematologic

Location: Texas Oncology-Arlington North

Phase: IV

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Arlington North

Phase: IV

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR CC-122+Rtx, FL R/R to Len View

Description: A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223, CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELLLYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001)

Indication: Lymphomas

Location: Texas Oncology-Arlington North

Phase: I

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Arlington North

Phase: I/II

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Myelofibrosis

Location: Texas Oncology-Arlington North

Phase: IV

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Arlington North

Phase: II

Title: Multiple Myeloma Patient Registry View

Description: Multiple Myeloma Patient Registry

Indication: Myelomas

Location: Texas Oncology-Arlington North

Phase: IV

Title: STAR BSC +/- LAN in Lung NETs [SPINET] View

Description: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Arlington North

Phase: III

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington North

Phase: III

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph3 Pembro+Epacadostat 2L UC View

Description: A Phase 3 Randomized, Double-Blind Clinical Study of Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo as a Treatment for Recurrent or Progressive Metastatic Urothelial Carcinoma in Patients who have Failed a First-Line Platinum-containing Chemotherapy Regimen for Advanced/Metastatic Disease (KEYNOTE-698/ECHO-303) (MK3475-KN698)

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington North

Phase: III

Texas Oncology-Arlington South

Title: STAR Open Label VT-464 Adv Breast Cancer View

Description: A Phase 1/2 Open-Label Study to Evaluate the Safety,Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel plus Dexamethasone (SEVI-D) in Subjects with Advanced Breast Cancer (INO-VT-464-CL-006)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: PHIII AuxLymphDisect VS AuxRad Node+Brst View

Description: A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (ct1-3 n1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Cape/tras +/- ONT-380 HER2+ mBC View

Description: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinibvs. Placebo in Combination with Capecitabine and Trastuzumab inPatients with Pretreated Unresectable Locally Advanced or MetastaticHER2+ Breast Carcinoma(HER2CLIMB) (ONT-380-206)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of AbemaciclibCombined with Standard Adjuvant Endocrine Therapy versusStandard Adjuvant Endocrine Therapy Alone in Patients withHigh Risk, Node Positive, Early Stage, Hormone ReceptorPositive, Human Epidermal Receptor 2 Negative, BreastCancer

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Carcinoid

Location: Texas Oncology-Arlington South

Phase: II

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Essential Thrombocythemia

Location: Texas Oncology-Arlington South

Phase: IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Hematologic

Location: Texas Oncology-Arlington South

Phase: IV

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Arlington South

Phase: IV

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR CC-122+Rtx, FL R/R to Len View

Description: A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223, CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELLLYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001)

Indication: Lymphomas

Location: Texas Oncology-Arlington South

Phase: I

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Arlington South

Phase: I/II

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Myelofibrosis

Location: Texas Oncology-Arlington South

Phase: IV

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Arlington South

Phase: II

Title: Multiple Myeloma Patient Registry View

Description: Multiple Myeloma Patient Registry

Indication: Myelomas

Location: Texas Oncology-Arlington South

Phase: IV

Title: STAR BSC +/- LAN in Lung NETs [SPINET] View

Description: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph3 Pembro+Epacadostat 2L UC View

Description: A Phase 3 Randomized, Double-Blind Clinical Study of Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo as a Treatment for Recurrent or Progressive Metastatic Urothelial Carcinoma in Patients who have Failed a First-Line Platinum-containing Chemotherapy Regimen for Advanced/Metastatic Disease (KEYNOTE-698/ECHO-303) (MK3475-KN698)

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington South

Phase: III

Texas Oncology-Bedford

Title: Phase III Randomized Study of Standard versus Accelerated Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients with Stage II-III Non-Small Cell Lung Cancer and Poor Performance Status View

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Title: Pragmatic Phase III Randomized Trial Of Proton Vs. Photon Therapy For Patients With Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (Radcomp) Consortium Trial View

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Biliary Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR INCB054828 in Cholangiocarcinoma View

Description: A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202)

Indication: Biliary Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Alisertib+Pac MBC/local recurBC 1&2 Ln View

Description: (USO 13033/ Millennium X14021) A Phase II, Multicenter, Randomized, Parallel Group Study to Compare Alisertib in Combination with Paclitaxel vs. Paclitaxel Alone in Patients with Metastatic or Locally Recurrent Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Post-Mastctmy/Lumpctmy XRT, Neoadj Chemo View

Description: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP B-51 / RTOG 1304)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Open Label VT-464 Adv Breast Cancer View

Description: A Phase 1/2 Open-Label Study to Evaluate the Safety,Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel plus Dexamethasone (SEVI-D) in Subjects with Advanced Breast Cancer (INO-VT-464-CL-006)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph II G1T28+Gem&Carb mTNBC View

Description: Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients with Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy (G1T28-04)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Cape/tras +/- ONT-380 HER2+ mBC View

Description: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinibvs. Placebo in Combination with Capecitabine and Trastuzumab inPatients with Pretreated Unresectable Locally Advanced or MetastaticHER2+ Breast Carcinoma(HER2CLIMB) (ONT-380-206)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph 3 Tesetaxel+Capecitabine mHER2- View

Description: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (ODO-TE-B301)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph2 MLN0128 + Fulves ER+/HER2- mBC View

Description: An Open-Label Phase 2 Study of MLN0128 (A TORC1/2 Inhibitor) in Combination WithFulvestrant in Women With ER-Positive/HER2-Negative Advanced or Metastatic BreastCancer That Has Progressed During or After Aromatase Inhibitor Therapy. (C31006)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Carcinoid

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Cervical Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Endometrial Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, ANDBEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IVOVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Gastric Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo+Ipi v Oxali+5FU, 1L Gastric/GEJ View

Description: CA209649: A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab plus Ipilimumab orNivolumab in Combination with Oxaliplatin plus Fluoropyrimidine versus Oxaliplatin plusFluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic Gastric orGastroesophageal Junction Cancer(CheckMate 649: CHECKpoint pathway and nivoluMab Clinical Trial Evaluation 649)

Indication: Gastric Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Head and Neck Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Bedford

Phase: IV

Title: Ublituximab+TGR-1202 Cross-over View

Description: (UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304

Indication: Leukemia

Location: Texas Oncology-Bedford

Phase: II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: Ph3 Nivo vs Plat-Doublet chemo NSCLC View

Description: Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC (CA209-816)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Bedford

Phase: II

Title: STAR CC-122+Rtx, FL R/R to Len View

Description: A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223, CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELLLYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001)

Indication: Lymphomas

Location: Texas Oncology-Bedford

Phase: I

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Bedford

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Bedford

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Mesothelioma

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Bedford

Phase: II

Title: STAR BSC +/- LAN in Lung NETs [SPINET] View

Description: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Bedford

Phase: III

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 NUC-1031 Pt-Resist Ovarian View

Description: A Phase II Open-Label Study of NUC-1031 in Patients with Platinum-Resistant Ovarian Cancer (PRO-105)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, ANDBEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IVOVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Erlotinib + ChemoRad Pancreas Adeno View

Description: A Phase II-R and A Phase III Trial Evaluating Both *Erlotinib (Ph II-R) and Chemoradiation (PhIII) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma (RTOG 0848)

Indication: Pancreatic Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Penile Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, ANDBEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IVOVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Peritoneal Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Rectal Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: II

Title: Molec Markers - solid malignant tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: IV

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Testicular Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thymomas

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thyroid Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph3 Pembro+Epacadostat 2L UC View

Description: A Phase 3 Randomized, Double-Blind Clinical Study of Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo as a Treatment for Recurrent or Progressive Metastatic Urothelial Carcinoma in Patients who have Failed a First-Line Platinum-containing Chemotherapy Regimen for Advanced/Metastatic Disease (KEYNOTE-698/ECHO-303) (MK3475-KN698)

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Uterine Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Vaginal Cancer

Location: Texas Oncology-Bedford

Phase: II

Texas Oncology-Fort Worth 12th Ave.

Title: A Retrospective Chart Review to Identify Common Factors Leading to Hospitalization of Patients with Gynecologic Cancers within 6 Months of Receiving Chemotherapy View

Indication: Miscellaneous

Location: Texas Oncology-Fort Worth 12th Ave.

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Biliary Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Brain Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Title: Ph1/2 Roval Tesirine Solid Tumor View

Description: SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Indication: Brain Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: Alisertib+Pac MBC/local recurBC 1&2 Ln View

Description: (USO 13033/ Millennium X14021) A Phase II, Multicenter, Randomized, Parallel Group Study to Compare Alisertib in Combination with Paclitaxel vs. Paclitaxel Alone in Patients with Metastatic or Locally Recurrent Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Title: STAR Open Label VT-464 Adv Breast Cancer View

Description: A Phase 1/2 Open-Label Study to Evaluate the Safety,Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel plus Dexamethasone (SEVI-D) in Subjects with Advanced Breast Cancer (INO-VT-464-CL-006)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: STAR Cape/tras +/- ONT-380 HER2+ mBC View

Description: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinibvs. Placebo in Combination with Capecitabine and Trastuzumab inPatients with Pretreated Unresectable Locally Advanced or MetastaticHER2+ Breast Carcinoma(HER2CLIMB) (ONT-380-206)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of AbemaciclibCombined with Standard Adjuvant Endocrine Therapy versusStandard Adjuvant Endocrine Therapy Alone in Patients withHigh Risk, Node Positive, Early Stage, Hormone ReceptorPositive, Human Epidermal Receptor 2 Negative, BreastCancer

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: III

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Carcinoid

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Cervical Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Cervical Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Title: Ph3 BBI-608/FOLFIRI +/- Bev, 2L mCRC View

Description: CanStem303C: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC)

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: III

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Esophageal Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Title: IMGN583, Folate Recept+ Ovrn [FORWARD 1] View

Description: FORWARD 1: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab soravtansine (IMGN853) Versus Investigator''s Choice of Chemotherapy in Women with Folate Receptor alpha-positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer (0403)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: III

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Gastric Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Head and Neck Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: PhIb/II BBI608/503+Sorafenib HCC View

Description: A Phase Ib/II Clinical Study of BBI608 in Combination with Sorafenib or BBI503 in Combination with Sorafenib in Adult Patients with Hepatocellular Carcinoma (BBI608-503-103HCC; formerly: BBIHCC-103)

Indication: Liver Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Liver Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: Ph2 Combo Therapies IO NSCLC-FRACTION View

Description: CA018-001/CA018-001A: Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Subjects with Advanced Non-small Cell Lung Cancer (FRACTION-Lung)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Ph 1a/1b Rovalpituzumab Extensive SCLC View

Description: SCRX001-004: A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients with Delta-Like Protein 3-Expressing Extensive Stage Small Cell Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Title: Ph1b/2 HBI8000+Nivo Advanced Solid Tumor View

Description: HBI-8000-302: A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Nivolumab in Patients with Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC) and Non-Small Cell Lung Cancer (NSCLC)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: Ph3b/4 Safety Nivo+Ipi 1L, 2L NSCLC View

Description: CA209-817: A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: III/IV

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: STAR CC-122+Rtx, FL R/R to Len View

Description: A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223, CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELLLYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Melanoma

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Title: Ph1b/2 HBI8000+Nivo Advanced Solid Tumor View

Description: HBI-8000-302: A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Nivolumab in Patients with Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC) and Non-Small Cell Lung Cancer (NSCLC)

Indication: Melanoma

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: Ph1/2 Roval Tesirine Solid Tumor View

Description: SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Indication: Melanoma

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: Ph3 Cobi + Atezo vs Pembro BRAF Melanoma View

Description: A PHASE III, OPEN-LABEL, MULTICENTER, TWO ARM, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF COBIMETINIB PLUS ATEZOLIZUMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED BRAFV600 WILD-TYPE MELANOMA (CO39722)

Indication: Melanoma

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: III

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Melanoma

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Mesothelioma

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: STAR BSC +/- LAN in Lung NETs [SPINET] View

Description: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: III

Title: Ph1/2 Roval Tesirine Solid Tumor View

Description: SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Title: Niraparib HRD+ Adv Ovrn post 1L [PRIMA] View

Description: PR-30-5017-C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response On Front-Line Platinum-Based Chemotherapy (PRIMA)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: III

Title: Ph2 NUC-1031 Pt-Resist Ovarian View

Description: A Phase II Open-Label Study of NUC-1031 in Patients with Platinum-Resistant Ovarian Cancer (PRO-105)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: IMGN583, Folate Recept+ Ovrn [FORWARD 1] View

Description: FORWARD 1: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab soravtansine (IMGN853) Versus Investigator''s Choice of Chemotherapy in Women with Folate Receptor alpha-positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer (0403)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: III

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Pancreatic Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Title: Ph1/2 Roval Tesirine Solid Tumor View

Description: SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Indication: Pancreatic Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Penile Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: IMGN583, Folate Recept+ Ovrn [FORWARD 1] View

Description: FORWARD 1: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab soravtansine (IMGN853) Versus Investigator''s Choice of Chemotherapy in Women with Folate Receptor alpha-positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer (0403)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: III

Title: Enzal +/- PI3 Kinase/mTOR inhib mCRPC View

Description: A Double-Blinded, Placebo-Controlled, Randomized Phase II Study ofEnzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414in Men with Metastatic Castration Resistant Prostate Cancer (GU 115/I6A-MC-CBBD)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Ph1/2 Roval Tesirine Solid Tumor View

Description: SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: Ph3 aPDL1/Atezo+Enza mCRPC View

Description: A PHASE III, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH ENZALUTAMIDE VERSUS ENZALUTAMIDE ALONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF AN ANDROGEN SYNTHESISINHIBITOR AND FAILURE OF, INELIGIBILITY FOR, OR REFUSAL OF A TAXANE REGIMEN - Roche CO39385

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: III

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: III

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Rectal Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Rectal Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Ph3 BBI-608/FOLFIRI +/- Bev, 2L mCRC View

Description: CanStem303C: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC)

Indication: Rectal Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: III

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: Ph1b/2 HBI8000+Nivo Advanced Solid Tumor View

Description: HBI-8000-302: A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Nivolumab in Patients with Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC) and Non-Small Cell Lung Cancer (NSCLC)

Indication: Renal Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: Ph2 Lenvatinib+evero RCC 2L View

Description: E7080-G000-218: A Randomized, Double-blind, Phase 2 Trial to Assess Safety and Efficacy of Lenvatinib at Two Different Starting Doses (18 mg vs. 14 mg QD) in Combination with Everolimus (5 mg QD) in Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment

Indication: Renal Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Lenvat+ever/pemb vs sunit 1L RCC [CLEAR] View

Description: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma(E7080-G000-307)(CLEAR)

Indication: Renal Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: III

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Title: Ph1/2 Roval Tesirine Solid Tumor View

Description: SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: PhIb/II BBI503+select therapy Adv Cancer View

Description: A Phase Ib/II Clinical Study of BBI503 in Combination with Selected Anti-Cancer Therapeutics in Adult Patients with Advanced Cancer - BBI503-201

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: Molec Markers - solid malignant tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: IV

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Testicular Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thymomas

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Ph1/2 Roval Tesirine Solid Tumor View

Description: SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Indication: Thyroid Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thyroid Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: STAR Ph3 Pembro+Epacadostat 2L UC View

Description: A Phase 3 Randomized, Double-Blind Clinical Study of Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo as a Treatment for Recurrent or Progressive Metastatic Urothelial Carcinoma in Patients who have Failed a First-Line Platinum-containing Chemotherapy Regimen for Advanced/Metastatic Disease (KEYNOTE-698/ECHO-303) (MK3475-KN698)

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: III

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Uterine Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Vaginal Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Texas Oncology-Fort Worth 8th Ave.

Title: STAR INCB054828 in Cholangiocarcinoma View

Description: A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202)

Indication: Biliary Cancer

Location: Texas Oncology-Fort Worth 8th Ave.

Phase: II

Title: STAR Cape/tras +/- ONT-380 HER2+ mBC View

Description: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinibvs. Placebo in Combination with Capecitabine and Trastuzumab inPatients with Pretreated Unresectable Locally Advanced or MetastaticHER2+ Breast Carcinoma(HER2CLIMB) (ONT-380-206)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth 8th Ave.

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Carcinoid

Location: Texas Oncology-Fort Worth 8th Ave.

Phase: II

Title: IMRT+/-Cetuximab H&N View

Description: A phase III study of postoperative radiation therapy (IMRT) +/- cetuximab for locally-advanced resected head and neck cancer (RTOG 0920)

Indication: Head and Neck Cancer

Location: Texas Oncology-Fort Worth 8th Ave.

Phase: III

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Fort Worth 8th Ave.

Phase: I/II

Title: STAR BSC +/- LAN in Lung NETs [SPINET] View

Description: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Fort Worth 8th Ave.

Phase: III

Title: STAR BSC +/- LAN in Lung NETs [SPINET] View

Description: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Fort Worth 8th Ave.

Phase: III

Title: STAR BSC +/- LAN in Lung NETs [SPINET] View

Description: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Fort Worth 8th Ave.

Phase: III

Title: Ph3Andro+HighRad +/- PelvicRad Prostate View

Description: Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth 8th Ave.

Phase: III

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth 8th Ave.

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth 8th Ave.

Phase: III

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Fort Worth 8th Ave.

Phase: II

Texas Oncology-Fort Worth Klabzuba

Title: STAR Cape/tras +/- ONT-380 HER2+ mBC View

Description: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinibvs. Placebo in Combination with Capecitabine and Trastuzumab inPatients with Pretreated Unresectable Locally Advanced or MetastaticHER2+ Breast Carcinoma(HER2CLIMB) (ONT-380-206)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Klabzuba

Phase: II

Title: IMRT+/-Cetuximab H&N View

Description: A phase III study of postoperative radiation therapy (IMRT) +/- cetuximab for locally-advanced resected head and neck cancer (RTOG 0920)

Indication: Head and Neck Cancer

Location: Texas Oncology-Fort Worth Klabzuba

Phase: III

Title: STAR CC-122+Rtx, FL R/R to Len View

Description: A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223, CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELLLYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Klabzuba

Phase: I

Title: STAR BSC +/- LAN in Lung NETs [SPINET] View

Description: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Fort Worth Klabzuba

Phase: III

Title: Ph3Andro+HighRad +/- PelvicRad Prostate View

Description: Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Klabzuba

Phase: III

Texas Oncology-Grapevine

Title: Phase III Randomized Study of Standard versus Accelerated Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients with Stage II-III Non-Small Cell Lung Cancer and Poor Performance Status View

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Title: Pragmatic Phase III Randomized Trial Of Proton Vs. Photon Therapy For Patients With Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (Radcomp) Consortium Trial View

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Biliary Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR INCB054828 in Cholangiocarcinoma View

Description: A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202)

Indication: Biliary Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Alisertib+Pac MBC/local recurBC 1&2 Ln View

Description: (USO 13033/ Millennium X14021) A Phase II, Multicenter, Randomized, Parallel Group Study to Compare Alisertib in Combination with Paclitaxel vs. Paclitaxel Alone in Patients with Metastatic or Locally Recurrent Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Open Label VT-464 Adv Breast Cancer View

Description: A Phase 1/2 Open-Label Study to Evaluate the Safety,Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel plus Dexamethasone (SEVI-D) in Subjects with Advanced Breast Cancer (INO-VT-464-CL-006)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: PHIII AuxLymphDisect VS AuxRad Node+Brst View

Description: A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (ct1-3 n1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph II G1T28+Gem&Carb mTNBC View

Description: Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients with Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy (G1T28-04)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Cape/tras +/- ONT-380 HER2+ mBC View

Description: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinibvs. Placebo in Combination with Capecitabine and Trastuzumab inPatients with Pretreated Unresectable Locally Advanced or MetastaticHER2+ Breast Carcinoma(HER2CLIMB) (ONT-380-206)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph 3 Tesetaxel+Capecitabine mHER2- View

Description: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (ODO-TE-B301)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph2 MLN0128 + Fulves ER+/HER2- mBC View

Description: An Open-Label Phase 2 Study of MLN0128 (A TORC1/2 Inhibitor) in Combination WithFulvestrant in Women With ER-Positive/HER2-Negative Advanced or Metastatic BreastCancer That Has Progressed During or After Aromatase Inhibitor Therapy. (C31006)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Carcinoid

Location: Texas Oncology-Grapevine

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Cervical Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Endometrial Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, ANDBEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IVOVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Gastric Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Nivo+Ipi v Oxali+5FU, 1L Gastric/GEJ View

Description: CA209649: A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab plus Ipilimumab orNivolumab in Combination with Oxaliplatin plus Fluoropyrimidine versus Oxaliplatin plusFluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic Gastric orGastroesophageal Junction Cancer(CheckMate 649: CHECKpoint pathway and nivoluMab Clinical Trial Evaluation 649)

Indication: Gastric Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Head and Neck Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Grapevine

Phase: IV

Title: Ublituximab+TGR-1202 Cross-over View

Description: (UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304

Indication: Leukemia

Location: Texas Oncology-Grapevine

Phase: II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: Ph3 Nivo vs Plat-Doublet chemo NSCLC View

Description: Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC (CA209-816)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR CC-122+Rtx, FL R/R to Len View

Description: A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223, CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELLLYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001)

Indication: Lymphomas

Location: Texas Oncology-Grapevine

Phase: I

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Grapevine

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Grapevine

Phase: I/II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Mesothelioma

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR BSC +/- LAN in Lung NETs [SPINET] View

Description: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Grapevine

Phase: III

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Grapevine

Phase: II

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, ANDBEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IVOVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Ovarian Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Penile Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, ANDBEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IVOVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Peritoneal Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Rectal Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: II

Title: Molec Markers - solid malignant tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: IV

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Testicular Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thymomas

Location: Texas Oncology-Grapevine

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thyroid Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph3 Pembro+Epacadostat 2L UC View

Description: A Phase 3 Randomized, Double-Blind Clinical Study of Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo as a Treatment for Recurrent or Progressive Metastatic Urothelial Carcinoma in Patients who have Failed a First-Line Platinum-containing Chemotherapy Regimen for Advanced/Metastatic Disease (KEYNOTE-698/ECHO-303) (MK3475-KN698)

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Uterine Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Vaginal Cancer

Location: Texas Oncology-Grapevine

Phase: II

No Phase

Title: Phase III Randomized Study of Standard versus Accelerated Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients with Stage II-III Non-Small Cell Lung Cancer and Poor Performance Status View

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Title: Phase III Randomized Study of Standard versus Accelerated Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients with Stage II-III Non-Small Cell Lung Cancer and Poor Performance Status View

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Title: Pragmatic Phase III Randomized Trial Of Proton Vs. Photon Therapy For Patients With Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (Radcomp) Consortium Trial View

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Title: Pragmatic Phase III Randomized Trial Of Proton Vs. Photon Therapy For Patients With Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (Radcomp) Consortium Trial View

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Title: A Retrospective Chart Review to Identify Common Factors Leading to Hospitalization of Patients with Gynecologic Cancers within 6 Months of Receiving Chemotherapy View

Indication: Miscellaneous

Location: Texas Oncology-Fort Worth 12th Ave.

Phase I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Brain Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Cervical Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Esophageal Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Liver Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Title: STAR CC-122+Rtx, FL R/R to Len View

Description: A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223, CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELLLYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001)

Indication: Lymphomas

Location: Texas Oncology-Arlington North

Phase: I

Title: STAR CC-122+Rtx, FL R/R to Len View

Description: A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223, CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELLLYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001)

Indication: Lymphomas

Location: Texas Oncology-Arlington South

Phase: I

Title: STAR CC-122+Rtx, FL R/R to Len View

Description: A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223, CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELLLYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001)

Indication: Lymphomas

Location: Texas Oncology-Bedford

Phase: I

Title: STAR CC-122+Rtx, FL R/R to Len View

Description: A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223, CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELLLYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Title: STAR CC-122+Rtx, FL R/R to Len View

Description: A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223, CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELLLYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Klabzuba

Phase: I

Title: STAR CC-122+Rtx, FL R/R to Len View

Description: A PHASE 1B, MULTI-CENTER, OPEN-LABEL STUDY OF NOVEL COMBINATIONS OF CC-122, CC-223, CC-292, AND RITUXIMAB IN DIFFUSE LARGE B-CELLLYMPHOMA AND FOLLICULAR LYMPHOMA (CC-122-DLBCL-001)

Indication: Lymphomas

Location: Texas Oncology-Grapevine

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Melanoma

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Title: Ph1 TSR-022 Adv Solid Tumors View

Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (4020-01-001)

Indication: Melanoma

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Pancreatic Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Rectal Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Title: Ph1 MSB0011359C Solid Tumors View

Description: A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications - EMD Serono EMR 200647-001

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I

Phase I/II

Title: Ph1/2 Roval Tesirine Solid Tumor View

Description: SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Indication: Brain Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Endometrial Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Head and Neck Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: PhIb/II BBI608/503+Sorafenib HCC View

Description: A Phase Ib/II Clinical Study of BBI608 in Combination with Sorafenib or BBI503 in Combination with Sorafenib in Adult Patients with Hepatocellular Carcinoma (BBI608-503-103HCC; formerly: BBIHCC-103)

Indication: Liver Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: Ph 1a/1b Rovalpituzumab Extensive SCLC View

Description: SCRX001-004: A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients with Delta-Like Protein 3-Expressing Extensive Stage Small Cell Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: Ph1b/2 HBI8000+Nivo Advanced Solid Tumor View

Description: HBI-8000-302: A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Nivolumab in Patients with Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC) and Non-Small Cell Lung Cancer (NSCLC)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Arlington North

Phase: I/II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 Tazemetostat r/r DLBCL & FL View

Description: An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B Cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma - E7438-G000-101

Indication: Lymphomas

Location: Texas Oncology-Fort Worth 8th Ave.

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Bedford

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Melanoma

Location: Texas Oncology-Grapevine

Phase: I/II

Title: Ph1b/2 HBI8000+Nivo Advanced Solid Tumor View

Description: HBI-8000-302: A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Nivolumab in Patients with Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC) and Non-Small Cell Lung Cancer (NSCLC)

Indication: Melanoma

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: Ph1/2 Roval Tesirine Solid Tumor View

Description: SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Indication: Melanoma

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: Ph1/2 Roval Tesirine Solid Tumor View

Description: SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: Ph1/2 Roval Tesirine Solid Tumor View

Description: SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Indication: Pancreatic Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: Ph1/2 Roval Tesirine Solid Tumor View

Description: SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Renal Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: Ph1b/2 HBI8000+Nivo Advanced Solid Tumor View

Description: HBI-8000-302: A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Nivolumab in Patients with Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC) and Non-Small Cell Lung Cancer (NSCLC)

Indication: Renal Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: Ph1/2 Roval Tesirine Solid Tumor View

Description: SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: PhIb/II BBI503+select therapy Adv Cancer View

Description: A Phase Ib/II Clinical Study of BBI503 in Combination with Selected Anti-Cancer Therapeutics in Adult Patients with Advanced Cancer - BBI503-201

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: Ph1/2 Roval Tesirine Solid Tumor View

Description: SCRX001-006: An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors

Indication: Thyroid Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: I/II

Title: PhIb/2 Lenvatinib (E7080)+Pembro Solids View

Description: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors (E7080-A001-111)

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Phase II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Biliary Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Biliary Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Biliary Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR INCB054828 in Cholangiocarcinoma View

Description: A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202)

Indication: Biliary Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR INCB054828 in Cholangiocarcinoma View

Description: A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202)

Indication: Biliary Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR INCB054828 in Cholangiocarcinoma View

Description: A Phase 2, Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy (INCB 54828-202)

Indication: Biliary Cancer

Location: Texas Oncology-Fort Worth 8th Ave.

Phase: II

Title: Alisertib+Pac MBC/local recurBC 1&2 Ln View

Description: (USO 13033/ Millennium X14021) A Phase II, Multicenter, Randomized, Parallel Group Study to Compare Alisertib in Combination with Paclitaxel vs. Paclitaxel Alone in Patients with Metastatic or Locally Recurrent Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Alisertib+Pac MBC/local recurBC 1&2 Ln View

Description: (USO 13033/ Millennium X14021) A Phase II, Multicenter, Randomized, Parallel Group Study to Compare Alisertib in Combination with Paclitaxel vs. Paclitaxel Alone in Patients with Metastatic or Locally Recurrent Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Alisertib+Pac MBC/local recurBC 1&2 Ln View

Description: (USO 13033/ Millennium X14021) A Phase II, Multicenter, Randomized, Parallel Group Study to Compare Alisertib in Combination with Paclitaxel vs. Paclitaxel Alone in Patients with Metastatic or Locally Recurrent Breast Cancer

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Open Label VT-464 Adv Breast Cancer View

Description: A Phase 1/2 Open-Label Study to Evaluate the Safety,Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel plus Dexamethasone (SEVI-D) in Subjects with Advanced Breast Cancer (INO-VT-464-CL-006)

Indication: Breast Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Open Label VT-464 Adv Breast Cancer View

Description: A Phase 1/2 Open-Label Study to Evaluate the Safety,Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel plus Dexamethasone (SEVI-D) in Subjects with Advanced Breast Cancer (INO-VT-464-CL-006)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Open Label VT-464 Adv Breast Cancer View

Description: A Phase 1/2 Open-Label Study to Evaluate the Safety,Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel plus Dexamethasone (SEVI-D) in Subjects with Advanced Breast Cancer (INO-VT-464-CL-006)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Open Label VT-464 Adv Breast Cancer View

Description: A Phase 1/2 Open-Label Study to Evaluate the Safety,Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel plus Dexamethasone (SEVI-D) in Subjects with Advanced Breast Cancer (INO-VT-464-CL-006)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: STAR Open Label VT-464 Adv Breast Cancer View

Description: A Phase 1/2 Open-Label Study to Evaluate the Safety,Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel plus Dexamethasone (SEVI-D) in Subjects with Advanced Breast Cancer (INO-VT-464-CL-006)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph II G1T28+Gem&Carb mTNBC View

Description: Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients with Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy (G1T28-04)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph II G1T28+Gem&Carb mTNBC View

Description: Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients with Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy (G1T28-04)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Cape/tras +/- ONT-380 HER2+ mBC View

Description: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinibvs. Placebo in Combination with Capecitabine and Trastuzumab inPatients with Pretreated Unresectable Locally Advanced or MetastaticHER2+ Breast Carcinoma(HER2CLIMB) (ONT-380-206)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Cape/tras +/- ONT-380 HER2+ mBC View

Description: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinibvs. Placebo in Combination with Capecitabine and Trastuzumab inPatients with Pretreated Unresectable Locally Advanced or MetastaticHER2+ Breast Carcinoma(HER2CLIMB) (ONT-380-206)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Cape/tras +/- ONT-380 HER2+ mBC View

Description: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinibvs. Placebo in Combination with Capecitabine and Trastuzumab inPatients with Pretreated Unresectable Locally Advanced or MetastaticHER2+ Breast Carcinoma(HER2CLIMB) (ONT-380-206)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: STAR Cape/tras +/- ONT-380 HER2+ mBC View

Description: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinibvs. Placebo in Combination with Capecitabine and Trastuzumab inPatients with Pretreated Unresectable Locally Advanced or MetastaticHER2+ Breast Carcinoma(HER2CLIMB) (ONT-380-206)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Klabzuba

Phase: II

Title: STAR Cape/tras +/- ONT-380 HER2+ mBC View

Description: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinibvs. Placebo in Combination with Capecitabine and Trastuzumab inPatients with Pretreated Unresectable Locally Advanced or MetastaticHER2+ Breast Carcinoma(HER2CLIMB) (ONT-380-206)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Cape/tras +/- ONT-380 HER2+ mBC View

Description: Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinibvs. Placebo in Combination with Capecitabine and Trastuzumab inPatients with Pretreated Unresectable Locally Advanced or MetastaticHER2+ Breast Carcinoma(HER2CLIMB) (ONT-380-206)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth 8th Ave.

Phase: II

Title: Ph2 MLN0128 + Fulves ER+/HER2- mBC View

Description: An Open-Label Phase 2 Study of MLN0128 (A TORC1/2 Inhibitor) in Combination WithFulvestrant in Women With ER-Positive/HER2-Negative Advanced or Metastatic BreastCancer That Has Progressed During or After Aromatase Inhibitor Therapy. (C31006)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 MLN0128 + Fulves ER+/HER2- mBC View

Description: An Open-Label Phase 2 Study of MLN0128 (A TORC1/2 Inhibitor) in Combination WithFulvestrant in Women With ER-Positive/HER2-Negative Advanced or Metastatic BreastCancer That Has Progressed During or After Aromatase Inhibitor Therapy. (C31006)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Carcinoid

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Carcinoid

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Carcinoid

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Carcinoid

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Carcinoid

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Carcinoid

Location: Texas Oncology-Fort Worth 8th Ave.

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Cervical Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Cervical Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Cervical Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Endometrial Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Endometrial Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Gastric Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Gastric Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Gastric Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Head and Neck Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Head and Neck Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Head and Neck Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ublituximab+TGR-1202 Cross-over View

Description: (UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304

Indication: Leukemia

Location: Texas Oncology-Bedford

Phase: II

Title: Ublituximab+TGR-1202 Cross-over View

Description: (UTX-TGR-204) A Multi-Center, Open-Label, Compassionate Use Extension Study of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304

Indication: Leukemia

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph2 Combo Therapies IO NSCLC-FRACTION View

Description: CA018-001/CA018-001A: Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Subjects with Advanced Non-small Cell Lung Cancer (FRACTION-Lung)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: STAR Brentux in older pts w/HL 1L View

Description: SGN35-015:A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above

Indication: Lymphomas

Location: Texas Oncology-Grapevine

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Mesothelioma

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Mesothelioma

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Mesothelioma

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: STAR Ph2 Itacitinib +/- Ruxo in MF View

Description: INCB 39110-209, An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

Indication: Myelofibrosis

Location: Texas Oncology-Grapevine

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph2 NUC-1031 Pt-Resist Ovarian View

Description: A Phase II Open-Label Study of NUC-1031 in Patients with Platinum-Resistant Ovarian Cancer (PRO-105)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 NUC-1031 Pt-Resist Ovarian View

Description: A Phase II Open-Label Study of NUC-1031 in Patients with Platinum-Resistant Ovarian Cancer (PRO-105)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Penile Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Penile Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Penile Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Enzal +/- PI3 Kinase/mTOR inhib mCRPC View

Description: A Double-Blinded, Placebo-Controlled, Randomized Phase II Study ofEnzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414in Men with Metastatic Castration Resistant Prostate Cancer (GU 115/I6A-MC-CBBD)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 Rucaparib mCRPC (TRITON 2) View

Description: TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib inPatients with Metastatic Castration-resistant Prostate Cancer Associated with Homologous Recombination Deficiency - CO-338-052

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth 8th Ave.

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Rectal Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Rectal Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Rectal Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph2 Lenvatinib+evero RCC 2L View

Description: E7080-G000-218: A Randomized, Double-blind, Phase 2 Trial to Assess Safety and Efficacy of Lenvatinib at Two Different Starting Doses (18 mg vs. 14 mg QD) in Combination with Everolimus (5 mg QD) in Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment

Indication: Renal Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Arlington North

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 Pembro Recurr/Meta Cut. SCC View

Description: A Phase II, Open-Labeled, Single Arm Study to Evaluate the Safety and Tolerability of Pembrolizumab in Participants with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (629)

Indication: Skin Cancer

Location: Texas Oncology-Fort Worth 8th Ave.

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Testicular Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Testicular Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Testicular Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thymomas

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thymomas

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thymomas

Location: Texas Oncology-Grapevine

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thyroid Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thyroid Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Thyroid Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Uterine Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Uterine Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Uterine Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Vaginal Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Vaginal Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: II

Title: Nivo in Advanced/Met Malignancies View

Description: An Open-label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CA209627)

Indication: Vaginal Cancer

Location: Texas Oncology-Grapevine

Phase: II

Phase III

Title: Post-Mastctmy/Lumpctmy XRT, Neoadj Chemo View

Description: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy (NSABP B-51 / RTOG 1304)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Adj Therapy Node+orHRNode-3-Inv TNBC View

Description: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer (NRG-BR003)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: PHIII AuxLymphDisect VS AuxRad Node+Brst View

Description: A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (ct1-3 n1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy

Indication: Breast Cancer

Location: Texas Oncology-Arlington North

Phase: III

Title: PHIII AuxLymphDisect VS AuxRad Node+Brst View

Description: A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (ct1-3 n1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: PHIII AuxLymphDisect VS AuxRad Node+Brst View

Description: A randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (ct1-3 n1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph 3 Tesetaxel+Capecitabine mHER2- View

Description: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (ODO-TE-B301)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph 3 Tesetaxel+Capecitabine mHER2- View

Description: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (ODO-TE-B301)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of AbemaciclibCombined with Standard Adjuvant Endocrine Therapy versusStandard Adjuvant Endocrine Therapy Alone in Patients withHigh Risk, Node Positive, Early Stage, Hormone ReceptorPositive, Human Epidermal Receptor 2 Negative, BreastCancer

Indication: Breast Cancer

Location: Texas Oncology-Arlington North

Phase: III

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of AbemaciclibCombined with Standard Adjuvant Endocrine Therapy versusStandard Adjuvant Endocrine Therapy Alone in Patients withHigh Risk, Node Positive, Early Stage, Hormone ReceptorPositive, Human Epidermal Receptor 2 Negative, BreastCancer

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: Ph3 Abemaciclib HR+ HER2- (monarchE) View

Description: (I3Y-MC-JPCF) monarchE: A Randomized, Open-Label, Phase 3 Study of AbemaciclibCombined with Standard Adjuvant Endocrine Therapy versusStandard Adjuvant Endocrine Therapy Alone in Patients withHigh Risk, Node Positive, Early Stage, Hormone ReceptorPositive, Human Epidermal Receptor 2 Negative, BreastCancer

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: III

Title: Ph3 BBI-608/FOLFIRI +/- Bev, 2L mCRC View

Description: CanStem303C: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC)

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: III

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, ANDBEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IVOVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, ANDBEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IVOVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: IMGN583, Folate Recept+ Ovrn [FORWARD 1] View

Description: FORWARD 1: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab soravtansine (IMGN853) Versus Investigator''s Choice of Chemotherapy in Women with Folate Receptor alpha-positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer (0403)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: III

Title: Nivo+Ipi v Oxali+5FU, 1L Gastric/GEJ View

Description: CA209649: A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab plus Ipilimumab orNivolumab in Combination with Oxaliplatin plus Fluoropyrimidine versus Oxaliplatin plusFluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic Gastric orGastroesophageal Junction Cancer(CheckMate 649: CHECKpoint pathway and nivoluMab Clinical Trial Evaluation 649)

Indication: Gastric Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Nivo+Ipi v Oxali+5FU, 1L Gastric/GEJ View

Description: CA209649: A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab plus Ipilimumab orNivolumab in Combination with Oxaliplatin plus Fluoropyrimidine versus Oxaliplatin plusFluoropyrimidine in Subjects with Previously Untreated Advanced or Metastatic Gastric orGastroesophageal Junction Cancer(CheckMate 649: CHECKpoint pathway and nivoluMab Clinical Trial Evaluation 649)

Indication: Gastric Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: IMRT+/-Cetuximab H&N View

Description: A phase III study of postoperative radiation therapy (IMRT) +/- cetuximab for locally-advanced resected head and neck cancer (RTOG 0920)

Indication: Head and Neck Cancer

Location: Texas Oncology-Fort Worth 8th Ave.

Phase: III

Title: IMRT+/-Cetuximab H&N View

Description: A phase III study of postoperative radiation therapy (IMRT) +/- cetuximab for locally-advanced resected head and neck cancer (RTOG 0920)

Indication: Head and Neck Cancer

Location: Texas Oncology-Fort Worth Klabzuba

Phase: III

Title: Ph3 Nivo vs Plat-Doublet chemo NSCLC View

Description: Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC (CA209-816)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Nivo vs Plat-Doublet chemo NSCLC View

Description: Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC (CA209-816)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 Cobi + Atezo vs Pembro BRAF Melanoma View

Description: A PHASE III, OPEN-LABEL, MULTICENTER, TWO ARM, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF COBIMETINIB PLUS ATEZOLIZUMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED BRAFV600 WILD-TYPE MELANOMA (CO39722)

Indication: Melanoma

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: III

Title: STAR BSC +/- LAN in Lung NETs [SPINET] View

Description: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Arlington North

Phase: III

Title: STAR BSC +/- LAN in Lung NETs [SPINET] View

Description: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR BSC +/- LAN in Lung NETs [SPINET] View

Description: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Bedford

Phase: III

Title: STAR BSC +/- LAN in Lung NETs [SPINET] View

Description: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: III

Title: STAR BSC +/- LAN in Lung NETs [SPINET] View

Description: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Fort Worth 8th Ave.

Phase: III

Title: STAR BSC +/- LAN in Lung NETs [SPINET] View

Description: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Fort Worth Klabzuba

Phase: III

Title: STAR BSC +/- LAN in Lung NETs [SPINET] View

Description: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR BSC +/- LAN in Lung NETs [SPINET] View

Description: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Fort Worth 8th Ave.

Phase: III

Title: STAR BSC +/- LAN in Lung NETs [SPINET] View

Description: A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg plus BSC vs. Placebo plus BSC for Tumour Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumours (Spinet) - Ipsen A-US-52030-328

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Fort Worth 8th Ave.

Phase: III

Title: Niraparib HRD+ Adv Ovrn post 1L [PRIMA] View

Description: PR-30-5017-C: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response On Front-Line Platinum-Based Chemotherapy (PRIMA)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: III

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, ANDBEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IVOVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, ANDBEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IVOVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Ovarian Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: IMGN583, Folate Recept+ Ovrn [FORWARD 1] View

Description: FORWARD 1: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab soravtansine (IMGN853) Versus Investigator''s Choice of Chemotherapy in Women with Folate Receptor alpha-positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer (0403)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: III

Title: Erlotinib + ChemoRad Pancreas Adeno View

Description: A Phase II-R and A Phase III Trial Evaluating Both *Erlotinib (Ph II-R) and Chemoradiation (PhIII) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma (RTOG 0848)

Indication: Pancreatic Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, ANDBEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IVOVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Peritoneal Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: PacCarboBev +/-Atezo, 1L Ovrn IMagyn050 View

Description: A PHASE III, MULTICENTER, RANDOMIZED, STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, ANDBEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STAGE IVOVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER - YO39523

Indication: Peritoneal Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: IMGN583, Folate Recept+ Ovrn [FORWARD 1] View

Description: FORWARD 1: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab soravtansine (IMGN853) Versus Investigator''s Choice of Chemotherapy in Women with Folate Receptor alpha-positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer (0403)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: III

Title: Ph3Andro+HighRad +/- PelvicRad Prostate View

Description: Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth 8th Ave.

Phase: III

Title: Ph3Andro+HighRad +/- PelvicRad Prostate View

Description: Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Klabzuba

Phase: III

Title: Ph3 aPDL1/Atezo+Enza mCRPC View

Description: A PHASE III, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH ENZALUTAMIDE VERSUS ENZALUTAMIDE ALONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF AN ANDROGEN SYNTHESISINHIBITOR AND FAILURE OF, INELIGIBILITY FOR, OR REFUSAL OF A TAXANE REGIMEN - Roche CO39385

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington North

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Rucaparib v PhysC mCRPC (TRITON3) View

Description: TRITON3: A Multicenter, Randomized, Open-label Phase 3 Study of Rucaparib versus Physician''s Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth 8th Ave.

Phase: III

Title: Ph3 BBI-608/FOLFIRI +/- Bev, 2L mCRC View

Description: CanStem303C: A Phase III Study of BBI-608 in combination with 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients with Previously Treated Metastatic Colorectal Cancer (CRC)

Indication: Rectal Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: III

Title: Lenvat+ever/pemb vs sunit 1L RCC [CLEAR] View

Description: A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma(E7080-G000-307)(CLEAR)

Indication: Renal Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: III

Title: STAR Ph3 Pembro+Epacadostat 2L UC View

Description: A Phase 3 Randomized, Double-Blind Clinical Study of Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo as a Treatment for Recurrent or Progressive Metastatic Urothelial Carcinoma in Patients who have Failed a First-Line Platinum-containing Chemotherapy Regimen for Advanced/Metastatic Disease (KEYNOTE-698/ECHO-303) (MK3475-KN698)

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington North

Phase: III

Title: STAR Ph3 Pembro+Epacadostat 2L UC View

Description: A Phase 3 Randomized, Double-Blind Clinical Study of Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo as a Treatment for Recurrent or Progressive Metastatic Urothelial Carcinoma in Patients who have Failed a First-Line Platinum-containing Chemotherapy Regimen for Advanced/Metastatic Disease (KEYNOTE-698/ECHO-303) (MK3475-KN698)

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph3 Pembro+Epacadostat 2L UC View

Description: A Phase 3 Randomized, Double-Blind Clinical Study of Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo as a Treatment for Recurrent or Progressive Metastatic Urothelial Carcinoma in Patients who have Failed a First-Line Platinum-containing Chemotherapy Regimen for Advanced/Metastatic Disease (KEYNOTE-698/ECHO-303) (MK3475-KN698)

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph3 Pembro+Epacadostat 2L UC View

Description: A Phase 3 Randomized, Double-Blind Clinical Study of Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo as a Treatment for Recurrent or Progressive Metastatic Urothelial Carcinoma in Patients who have Failed a First-Line Platinum-containing Chemotherapy Regimen for Advanced/Metastatic Disease (KEYNOTE-698/ECHO-303) (MK3475-KN698)

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: III

Title: STAR Ph3 Pembro+Epacadostat 2L UC View

Description: A Phase 3 Randomized, Double-Blind Clinical Study of Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo as a Treatment for Recurrent or Progressive Metastatic Urothelial Carcinoma in Patients who have Failed a First-Line Platinum-containing Chemotherapy Regimen for Advanced/Metastatic Disease (KEYNOTE-698/ECHO-303) (MK3475-KN698)

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: III

Phase III/IV

Title: Ph3b/4 Safety Nivo+Ipi 1L, 2L NSCLC View

Description: CA209-817: A Phase IIIb/IV Safety and Efficacy Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Non-Small Cell Lung Cancer

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: III/IV

Phase IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Essential Thrombocythemia

Location: Texas Oncology-Arlington North

Phase: IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Essential Thrombocythemia

Location: Texas Oncology-Arlington South

Phase: IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Hematologic

Location: Texas Oncology-Arlington North

Phase: IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Hematologic

Location: Texas Oncology-Arlington South

Phase: IV

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Arlington North

Phase: IV

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Arlington South

Phase: IV

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Bedford

Phase: IV

Title: informCLL™ Registry View

Description: informCLL™: A Disease Registry for Patients with Chronic Lymphocytic Leukemia (PCYC-1134M-CA)

Indication: Leukemia

Location: Texas Oncology-Grapevine

Phase: IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Myelofibrosis

Location: Texas Oncology-Arlington North

Phase: IV

Title: Ph IV Obsv LowRisk MF [MOST] View

Description: Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (MOST) (INCB-MA-MF-401)

Indication: Myelofibrosis

Location: Texas Oncology-Arlington South

Phase: IV

Title: Multiple Myeloma Patient Registry View

Description: Multiple Myeloma Patient Registry

Indication: Myelomas

Location: Texas Oncology-Arlington North

Phase: IV

Title: Multiple Myeloma Patient Registry View

Description: Multiple Myeloma Patient Registry

Indication: Myelomas

Location: Texas Oncology-Arlington South

Phase: IV

Title: Molec Markers - solid malignant tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: IV

Title: Molec Markers - solid malignant tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth 12th Ave.

Phase: IV

Title: Molec Markers - solid malignant tumors View

Description: The Circulating Cell-free Genome Atlas (CCGA) Study (GRAIL-001)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: IV